BBOT

BridgeBio Oncology Therapeutics, Inc.

Contracts

Total Value

Stock Metrics

16.3%

Short % Float

20.8d to cover · Moderate squeeze

70.1%

Inst % Float

10 holders · 2026-06-30

Cormorant Asset Ma

Top Holder

22.3% of float

35.8M sh

Public Float

52/100

Dilution Score

High

27 mo

Cash Runway

Verified regulatory filings & proprietary analysis.

Dilution Risk

52/100

HIGH

Inst: 70.11% · Top: Cormorant Asset Management, LP

Biotech Analytics

Oncology

18.03

Dilution Risk: HIGHSqueeze risk: MODERATEBiotech Grade: F

Insider Buying0

Publications100

Dilution Risk52

Clinical Trials12

Short Interest50